ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $162.29M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 1.16M
Average 0.62M
Returns on capital
ProQR Therapeutics N.V. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-82.1%
avg -62.9%
ROIC
-49.8%
avg -43.3%
ROA
-36.0%
avg -37.7%
Analysis
ROA is currently the strongest return metric at -36.0% versus its period average of -37.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Daniel Anton de Boer | Founder, CEO & Executive Director | EUR 1.05M | 43 | 500.00K | 0.47% |
Gerard Platenburg | Co-Founder, Chief Scientific Officer & Executive Director | EUR 644.84K | 62 | — | — |
Golnar Karimian | Head of Hepatology | — | — | — | — |
Christopher Hart | Chief Data & AI Officer | — | — | — | — |
Dennis Hom | Chief Financial Officer | — | 51 | 250.00K | 0.24% |
Sandra van der Kolk | Junior Financial Controller | — | — | — | — |
Sarah Cue Kiely | Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Sheila Sponselee | Chief People & Operations Officer | — | 42 | — | — |
Cristina Lopez Lopez | Chief Medical Officer | — | 50 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 31, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$1.34M
Sells
0
$0.00
Net Transaction Value
+$1.34M
Net buying
Most Active
de Boer Daniel Anton
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 31, 26Jul 31, 2026 | de Boer Daniel Anton Direct | Buy | $354K$353,960.00 |
| Jul 17, 26Jul 17, 2026 | Filius Bart Direct | Buy | $257.9K$257,925.00 |
| Jul 9, 26Jul 9, 2026 | de Boer Daniel Anton Direct | Buy | $261K$261,000.00 |
| Jul 7, 26Jul 7, 2026 | de Boer Daniel Anton Direct | Buy | $238.5K$238,500.00 |
| Jun 26, 26Jun 26, 2026 | Filius Bart Direct | Buy | $231K$231,000.00 |
Summary
Insiders reported 5 buys worth $1.34M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.34M. de Boer Daniel Anton was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +62.0% | +48.5% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +62.0% over three years. Forward estimates point to Revenue at +48.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does ProQR Therapeutics N.V. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PRQR's management, answered from reported figures.
Who manages PRQR?
ProQR Therapeutics N.V. (PRQR) lists 9 active executives. The top listed executive is Golnar Karimian, Head of Hepatology.
Are PRQR insiders buying or selling?
Recent insider activity shows net buying of $1.36M.
Continue the stock analysis
Jump to another research area for this company.